Advertisement

Advertisement

2024 ASH Annual Meeting

Hematologic Malignancies

Studies Point to the Role of Diet in Hematologic Malignancies

According to research reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, a link seems to exist between hematologic malignancies and dietary components. The spea...

Lymphoma

Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma

A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, demonstrated durable responses to brexucabtagene autoleucel in patients with Br...

Hematologic Malignancies
Leukemia
Genomics/Genetics

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

First responders who worked at Ground Zero in the aftermath of the 2001 attacks on the World Trade Center in New York City were three times more likely to have genetic changes associated with an incre...

Hematologic Malignancies
Leukemia

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL

At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 883), Alexey Danilov, MD, PhD, of the Department of Hematology & Hematopoietic Cell Transplantation at Ci...

Lymphoma
Issues in Oncology

Autologous Stem Cell Transplantation May Not Improve Survival in Patients With MCL and Undetectable Minimal Residual Disease

Researchers have revealed that high-dose chemotherapy followed by autologous stem cell transplantation may not benefit patients with mantle cell lymphoma (MCL) who are in remission following initial t...

Leukemia
Immunotherapy
Issues in Oncology

Blinatumomab in Combination With Chemotherapy May Improve Survival in Pediatric Patients Newly Diagnosed With B-Cell Precursor ALL

The addition of blinatumomab to chemotherapy may improve disease-free survival in pediatric patients newly diagnosed with National Cancer Institute (NCI) standard-risk B-cell acute lymphoblastic leuke...

Leukemia

Bicistronic CAR T-Cell Therapy Achieved Durable Remissions in Children With Relapsed/Refractory B-Cell ALL

A follow-up study investigating the coadministration of CD19- and CD22-targeted chimeric antigen receptor (CAR) T-cell therapy in children with relapsed or refractory B-cell acute lymphoblastic leukem...

Hematologic Malignancies

Fiber-Rich Diet May Help Prevent Complications After Stem Cell Transplant

Consuming a high-fiber diet after undergoing stem cell transplantation may help to reduce the risk of graft-vs-host disease (GVHD) by cultivating a healthy gut microbiome, according to research presen...

Leukemia
Lymphoma
Issues in Oncology

Pirtobrutinib May Improve Survival Outcomes in Pretreated Patients With CLL or SLL

Researchers have found that the noncovalent Bruton's tyrosine kinase inhibitor (BTK) pirtobrutinib may offer superior progression-free survival in adults with chronic lymphocytic leukemia (CLL) or sma...

Leukemia
Issues in Oncology

Combination of Two Oral Agents May Improve Progression-Free Survival in Patients With Previously Untreated CLL

A combination of the oral drugs acalabrutinib and venetoclax may be more effective at improving progression-free survival and minimizing serious adverse events in patients with previously untreated ch...

Multiple Myeloma

High-Fiber Diet May Slow Disease Progression to Multiple Myeloma

Recent data suggest that a plant-based diet rich in fiber may help to improve the outlook for people with precursor conditions that can lead to multiple myeloma. The research, which involved a 12-week...

hematologic malignancies

Erik Thiele Orberg, MD, PhD, on Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined by Microbial Metabolite Profiles and Linked to Long-Term Outcomes

Erik Thiele Orberg, MD, PhD, of University Hospital Regensburg, shares findings of a longitudinal, prospective study investigating microbial and metabolite recovery in the post-transplant period. He d...

hematologic malignancies

Hannah Choe, MD, on Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study

Hannah Choe, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, reviews results from a secondary analysis of the phase 2 AGAVE-201 study, which assessed axatilimab, ...

Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, on the Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: A Multi-Center Observational Study

Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, of Fred Hutch Cancer Center and the University of Washington School of Medicine, presented results of a prospective, multicenter observational study ac...

hematologic malignancies

Jenny Paredes, PhD, on How Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical GVHD Models

Jenny Paredes, PhD, of City of Hope National Medical Center, discusses a study investigating the effects of dietary fiber on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell...

leukemia

Matthew S. Davids, MD, MMSc, on Triplet Therapy of Acalabrutinib, Venetoclax, and Obinutuzumab: Focus on TP53-Aberrant CLL

Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, Boston, discusses the primary endpoint evaluation of a phase II trial of the triplet regimen of acalabrutinib, venetoclax, and obinutuzuma...

hematologic malignancies

John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib

John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses early results from the ongoing phase I/IB IMproveMF trial, which is evaluating the safety and activity of the novel combi...

hematologic malignancies

John O. Mascarenhas, MD, on Relapsed/Refractory Myelofibrosis: Navtemadlin vs Best Available Therapy After JAK Inhibitor Treatment

John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses the results of the phase III BOREAS study evaluating the efficacy and safety of single-agent navtemadlin vs best availabl...

lymphoma

Timothy S. Fenske, MD, on Lack of Benefit of Autologous Hematopoietic Cell Transplantation in Mantle Cell Lymphoma Patients in First Complete Remission With Undetectable Minimal Residual Disease

Timothy S. Fenske, MD, of the Medical College of Wisconsin presented an initial report from the ECOG-ACRIN EA4151 phase III randomized trial exploring outcomes of autologous hematopoietic cell transpl...

leukemia

Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease

Rachel E. Rau, MD, of Seattle Children’s Hospital, and Sumit Gupta, MD, PhD, of the Hospital for Sick Children in Toronto, review results from Children’s Oncology Group Study AALL1731, which assessed ...

leukemia

Nitin Jain, MD, on First-Line Treatment With Pirtobrutinib-Based Regimen in CLL

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, Houston, discusses the results of a recent trial (Abstract 1011) evaluating the time-limited, combination therapy of the noncovale...

leukemia

Danielle Wolfe Cohen, MD, on Mechanisms of Relapse in B-Cell Acute Lymphoblastic Leukemia

Danielle Wolfe Cohen, MD, of the William L. Carroll Laboratory at New York University Grossman School of Medicine, describes data illuminating the role of an inflammatory phenotype in driving clonal e...

leukemia

Anne Sophie Michallet, MD, PhD, on MRD-Guided vs Standard Combination Therapy for Select Untreated Patients With CLL

Anne Sophie Michallet, MD, PhD, of Centre Léon Bérard Hospital, Lyon, France, discusses the final results of the phase II ERADIC trial (Abstract 584), which compared measurable residual disease (MRD)-...

Lymphoma
Issues in Oncology

Loncastuximab Tesirine May Improve Outcomes in High-Risk Follicular Lymphoma, Marginal Zone Lymphoma

The antibody loncastuximab tesirine may offer a benefit in patients with high-risk follicular lymphoma and marginal zone lymphoma, according to the findings of two clinical trials presented by Alderuc...

Symptom Management
Supportive Care

Rilzabrutinib Found Safe and Effective for Refractory Immune Thrombocytopenia

The experimental drug rilzabrutinib was well tolerated and generated an increase in platelet counts among some adults with immune thrombocytopenia (ITP) who had not experienced lasting improvements w...

Multiple Myeloma

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

An analysis of the results from the ongoing randomized phase III AQUILA study found that daratumumab monotherapy was well tolerated and demonstrated a clinically meaningful and significant benefit in ...

Leukemia

Lower Socioeconomic Status Impacts AML Patients’ Ability to Receive Hematopoietic Cell Transplantation

A large prospective observational study of patients with acute myeloid leukemia (AML) has found that lower socioeconomic status is a barrier to accessing hematopoietic cell transplantation (HCT) but ...

Lymphoma
Immunotherapy

Preclinical Findings Show Ketogenic Diet Enhances CAR T-Cell Function, Improves Tumor Control

Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest that a ketogenic diet may enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy...

leukemia

Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, Boston, discusses the findings from the prespecified interim analysis of the phase III AMPLIFY trial (Abstract 1009), which compared fixed-...

lymphoma

Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)

Maayan Levy, PhD, and Marco Ruella, MD, of the University of Pennsylvania, Perelman School of Medicine, discuss findings on whether ketogenic diet-derived BHB can be provided as a dietary intervention...

hematologic malignancies
supportive care

Nikolaos Katsivelos, MD, and John Levine, MD, MS, on How Serial Clinical and Biomarker Monitoring During Treatment Can Stratify Patients With Low-Risk GVHD

Nikolaos Katsivelos, MD, and John Levine, MD, MS, of Icahn School of Medicine at Mount Sinai report on an investigation into the potential for serial monitoring of graft-versus-host disease (GVHD) sym...

leukemia

Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, Boston, discusses the findings from the prespecified interim analysis of the phase III AMPLIFY trial (Abstract 1009), which compared fixed-...

Hematologic Malignancies

ASH Announces Recipients of 2024 ASH Advocacy Awards

The American Society of Hematology (ASH) honored Rep. Michael Burgess, MD (R-TX) and Centers for Disease Control and Prevention (CDC) health scientist Mary Hulihan, DrPH, for their leadership on is...

Hematologic Malignancies

ASH to Present 2024 Honorific Awards at Annual Meeting

The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Ex...

Advertisement

Advertisement




Advertisement